The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, ...

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Faun1083 has demonstrated positive in-vivo efficacy in multiple preclinical animal models, including rat sugen hypoxia and ...

The section presents a review of diastolic congestive heart failure, commonly called HFpEF. Reviews of systolic congestive HF, or HFrEF, valvular heart disease, pulmonary hypertension and right HF ...

The message is that an early decrease in eGFR with finerenone should not lead to stopping the medication, say HF experts.

The company is developing TX45 to treat group 2 pulmonary hypertension in patients with preserved ejection fraction heart failure or known as HFpEF. The goal for Tectonic for 2025 is beating AZ ...

Alleviant Medical announced that it received FDA investigational device exemption and breakthrough device designation for its atrial shunt.

The administration of potassium nitrate (KNO3) does not improve exercise capacity or quality of life in patients with heart failure with preserved ejection fraction (HFpEF), despite increasing ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF ...